50% off the $29.99 Custom Kit. Use at checkout:
⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF
AEO Score: 4/10
Monitoring for AI engine activity
In the Engagemii AEO index
#310,961 of 477,740 in Healthcare for AI visibility
What this score means
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF just got measured.
4/10 means BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
About BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF
BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF is a brand in the healthcare category. View their AI visibility score and details below.
Key Topics
Details
Industry: Healthcare
breakwaterphase3-infographic.comAI Visibility Breakdown
1
Structured Data
7
Content Structure
6
Entity Clarity
3
E-E-A-T Signals
6
Technical AEO
2
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Trust Is the Product. AI Is How You Build It at Scale.
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF.
Source & Attribution
Scored by Engagemii on July 15, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/breakwaterphase3-infographic
Cite this score: Engagemii (2026). "AEO Score for BREAKWATER: Phase 3 Study of Encorafenib, Cetuximab and Chemotherapy in BRAF." Retrieved from https://engagemii.com/aeo/brands/breakwaterphase3-infographic
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform